Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-Sulfonamide-[4-(Thiomethylaminobutane)]Benzamide is an experimental small molecule drug belonging to the benzenesulfonamides class, with the chemical formula C12H19N3O3S2 and DrugBank ID DB04002. It has not been approved for use in any country and is currently classified as preclinical or experimental. The compound is known to target carbonic anhydrase 2 (CA2), an enzyme involved in regulating acid-base balance and fluid secretion. Inhibition of carbonic anhydrase 2 can have therapeutic applications in conditions such as glaucoma, epilepsy, and certain edematous states, though this specific compound does not have any approved indications or clinical trial activity reported[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-Sulfonamide-[4-(Thiomethylaminobutane)]Benzamide.